Collectively, our in vivo data demonstrate that DC101-mediated VEGFR2 inhibition was sufficient to delay tumor growth in alveolar and embryonal RMS, DSRCT, Ewing’s sarcoma, synovial sarcoma, and neuroblastoma. This evidence concerns the gene KDR and Ewing sarcoma.